Takayanagi I, Koike K
Gen Pharmacol. 1985;16(3):265-7. doi: 10.1016/0306-3623(85)90080-1.
A beta-adrenoceptor blocking agent, befunolol, which is clinically used in the treatment of glaucoma in Japan, was found to have intrinsic sympathomimetic activities in isolated right atria, trachea and taenia caecum of guinea pig (intrinsic activities are 0.22-0.28). The pD2-values of befunolol estimated in the isolated organs were significantly different from its pA2-values against isoprenaline. A possible explanation of our findings would to be as follows: befunolol interacts with the beta-adrenoceptor where there may be two different sites: one site for agonistic action and the other for competitive antagonistic action. Both sites are supposed to be mutually exclusive through unknown mechanisms. The intrinsic activity of befunolol may be equal to its selectivity for both the sites.
一种β-肾上腺素受体阻断剂倍他洛尔,在日本临床上用于治疗青光眼,研究发现其在豚鼠离体右心房、气管和盲肠带中具有内在拟交感活性(内在活性为0.22 - 0.28)。在离体器官中测得的倍他洛尔的pD2值与其对异丙肾上腺素的pA2值有显著差异。对我们研究结果的一种可能解释如下:倍他洛尔与β-肾上腺素受体相互作用,其中可能存在两个不同位点:一个用于激动作用,另一个用于竞争性拮抗作用。这两个位点通过未知机制被认为是相互排斥的。倍他洛尔的内在活性可能与其对这两个位点的选择性相等。